Argent BioPharma Limited (RGTLF)

Market Cap	4.42M
Revenue (ttm)	183.08K
Net Income (ttm)	-14.00M
Shares Out	n/a
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900
Average Volume	70,017
Open	0.1110
Previous Close	0.1501
Day's Range	0.1110 - 0.1110
52-Week Range	0.0577 - 0.5683
Beta	0.50
RSI	43.43
Earnings Date	May 29, 2025

About Argent BioPharma

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the tr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGTLF

Financial Performance

In 2024, Argent BioPharma's revenue was 891,083, a decrease of -73.70% compared to the previous year's 3.39 million. Losses were -17.53 million, -15.81% less than in 2023.

Financial numbers in AUD